LYON, France, Nov. 14, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer, announced it will release its third quarter 2007 financial results Monday, November 26, 2007 after the market close. Management will host a conference call Tuesday, November 27 at 10:30 a.m. Eastern Time. This schedule accommodates the U.S. Thanksgiving holidays and closing requirements for EDAP's recently completed $20 million capital raise for its ongoing Clinical Phase III Trial of the Ablatherm-HIFU system for localized prostate cancer.
Marc Oczachowski, CEO, highlighted: "Our HIFU division confirmed its revenue progression with a 39% third quarter increase compared to last year's third quarter and a 21% over the nine months. Our RPP business showed a nice 37% increase over the nine months. The third quarter included the sale of 8 Sonolith units and 1 Ablatherm, this period being typically a slow quarter due to seasonal trends in Europe. We, however, entered the fourth quarter with a strong backlog including two Ablatherm units already purchased and delivered. We are extremely enthusiastic in concluding the year with a good fourth quarter as this period is generally a strong one due to the end of year hospital purchasing. In Europe, our marketing and sales teams are focused on expanding our businesses at an accelerating pace in established key countries and in new markets. Our U.S. clinical team is moving forward in finalizing site selection for our FDA trials and accelerating patient recruitment with the support of a specialized PR agency just hired. The recent fundraising has definitely been secured at the appropriate time, and we now have the financial means to achieve our U.S. ambitions."
Interested investors may join the November 27 call live by dialing (866) 463-5401 from the United States or +1 (212) 457-9857 from international locations and entering PIN code 862841#. Investors may also listen to the live call online at www.edap-tms.com. Investors unable to join the call can access a playback of the conference call by telephone or online. To access the replay, please dial (866) 439-4729 and using access code 345663# beginning one hour after the end of the call until December 4, 2007, or visit the company's Web site at www.edap-tms.com.
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is a treatment for patients with newly diagnosed localized prostate cancer or who have failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
To sign up for alerts please visit: http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0
In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.